Market Cap 8.16B
Revenue (ttm) 290.52M
Net Income (ttm) 89.16M
EPS (ttm) N/A
PE Ratio 43.35
Forward PE 34.07
Profit Margin 30.69%
Debt to Equity Ratio 0.00
Volume 167,849
Avg Vol 295,888
Day's Range N/A - N/A
Shares Out 29.00M
Stochastic %K 41%
Beta 0.46
Analysts Strong Sell
Price Target $279.60

Company Profile

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treati...

Industry: Biotechnology
Sector: Healthcare
Phone: 412 586 5830
Address:
2100 Wharton Street, Suite 701, Pittsburgh, United States
BioTechHealthX
BioTechHealthX Jan. 25 at 4:44 PM
$KRYS Krystal Biotech, Inc. (NASDAQ: KRYS) has evolved from a niche gene therapy developer into a commercial-stage biotech. With KRYS stock increasingly discussed among NASDAQ biotech investors, this background explains the growing interest. https://biotechhealthx.com/biotech-news/why-krystal-biotech-krys-is-becoming-a-name-investors-cant-ignore/
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 23 at 1:14 AM
$KRYS Share Price: $289.52 Contract Selected: Aug 21, 2026 $290 Calls Buy Zone: $37.06 – $45.78 Target Zone: $64.24 – $78.51 Potential Upside: 64% ROI Time to Expiration: 210 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
erevnon
erevnon Jan. 22 at 7:48 PM
B of A Securities maintains Krystal Biotech $KRYS at Buy and raises the price target from $288 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
IN0V8
IN0V8 Jan. 22 at 3:43 PM
$KRYS BofA Global Research raises price objective to $318 from $288
0 · Reply
BioRich
BioRich Jan. 17 at 11:43 PM
$KRYS Looking exceptional for a steady climb (or BO notice this week). Overall, impressed.
0 · Reply
Yurd
Yurd Jan. 17 at 2:23 AM
$KRYS So many biotech managements are great at science but have absolutely no clue how to run a business profitably. They couldn't make $100 million annual revenue cover SG&A, much less turn a tidy profit with it. This management is the rare disciplined operator with a commercial mindset. Rather than trying to build an empire, they run a fast machine. Good on ya.
0 · Reply
JordanBelfortsNephew
JordanBelfortsNephew Jan. 14 at 3:21 PM
$KRYS SMH and i thought i made a good decision selling this a year ago at $195 🤦🤦🤦🤦🤦
0 · Reply
Ortho91
Ortho91 Jan. 13 at 9:47 PM
$KRYS en fuego
0 · Reply
Stackdoe1
Stackdoe1 Jan. 13 at 9:16 PM
Tomorrow 🫡 ​$PKX $KRYS $KMT $WRBY
0 · Reply
ZacksResearch
ZacksResearch Jan. 12 at 7:13 PM
$KRYS surges 73.9% in a year — what’s driving the momentum? 🚀 🔥 Strong Vyjuvek uptake in 2025 in the US, EU, Japan 🔬 Expanding rare disease pipeline with key programs like KB801 for NK & KB407 for CF 💼 Zacks Rank #1 (Strong Buy) Discover the full growth story here 👉 https://www.zacks.com/stock/news/2816016/krys-reports-preliminary-results-for-2025-outlines-2026-objectives?cid=sm-stocktwits-2-2816016-body-28516&ADID=SYND_STOCKTWITS_TWEET_2_2816016_BODY_28516
0 · Reply
Latest News on KRYS
Krystal Biotech: Beyond VYJUVEK Commercialization

Jan 16, 2026, 7:45 AM EST - 11 days ago

Krystal Biotech: Beyond VYJUVEK Commercialization


Krystal Biotech: Vyjuvek Gene Therapy Well Positioned For Growth

Nov 16, 2025, 9:00 AM EST - 2 months ago

Krystal Biotech: Vyjuvek Gene Therapy Well Positioned For Growth


Krystal Biotech, Inc. (KRYS) Q3 2025 Earnings Call Transcript

Nov 3, 2025, 11:46 AM EST - 3 months ago

Krystal Biotech, Inc. (KRYS) Q3 2025 Earnings Call Transcript


Krystal Biotech, Inc. (KRYS) Q2 2025 Earnings Call Transcript

Aug 4, 2025, 12:42 PM EDT - 6 months ago

Krystal Biotech, Inc. (KRYS) Q2 2025 Earnings Call Transcript


Krystal Biotech, Inc. (KRYS) Q1 2025 Earnings Call Transcript

May 6, 2025, 2:43 PM EDT - 9 months ago

Krystal Biotech, Inc. (KRYS) Q1 2025 Earnings Call Transcript


Krystal Biotech to Present at Upcoming Scientific Conferences

Apr 24, 2025, 8:00 AM EDT - 9 months ago

Krystal Biotech to Present at Upcoming Scientific Conferences


Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer

Apr 7, 2025, 4:30 PM EDT - 10 months ago

Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer


Krystal Biotech, Inc. (KRYS) Q4 2024 Earnings Call Transcript

Feb 19, 2025, 11:43 AM EST - 1 year ago

Krystal Biotech, Inc. (KRYS) Q4 2024 Earnings Call Transcript


Krystal Biotech to Present at Upcoming Investor Conferences

Nov 27, 2024, 7:00 AM EST - 1 year ago

Krystal Biotech to Present at Upcoming Investor Conferences


Krystal Biotech, Inc. (KRYS) Q1 2024 Earnings Call Transcript

May 6, 2024, 11:44 AM EDT - 1 year ago

Krystal Biotech, Inc. (KRYS) Q1 2024 Earnings Call Transcript


BioTechHealthX
BioTechHealthX Jan. 25 at 4:44 PM
$KRYS Krystal Biotech, Inc. (NASDAQ: KRYS) has evolved from a niche gene therapy developer into a commercial-stage biotech. With KRYS stock increasingly discussed among NASDAQ biotech investors, this background explains the growing interest. https://biotechhealthx.com/biotech-news/why-krystal-biotech-krys-is-becoming-a-name-investors-cant-ignore/
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 23 at 1:14 AM
$KRYS Share Price: $289.52 Contract Selected: Aug 21, 2026 $290 Calls Buy Zone: $37.06 – $45.78 Target Zone: $64.24 – $78.51 Potential Upside: 64% ROI Time to Expiration: 210 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
erevnon
erevnon Jan. 22 at 7:48 PM
B of A Securities maintains Krystal Biotech $KRYS at Buy and raises the price target from $288 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
IN0V8
IN0V8 Jan. 22 at 3:43 PM
$KRYS BofA Global Research raises price objective to $318 from $288
0 · Reply
BioRich
BioRich Jan. 17 at 11:43 PM
$KRYS Looking exceptional for a steady climb (or BO notice this week). Overall, impressed.
0 · Reply
Yurd
Yurd Jan. 17 at 2:23 AM
$KRYS So many biotech managements are great at science but have absolutely no clue how to run a business profitably. They couldn't make $100 million annual revenue cover SG&A, much less turn a tidy profit with it. This management is the rare disciplined operator with a commercial mindset. Rather than trying to build an empire, they run a fast machine. Good on ya.
0 · Reply
JordanBelfortsNephew
JordanBelfortsNephew Jan. 14 at 3:21 PM
$KRYS SMH and i thought i made a good decision selling this a year ago at $195 🤦🤦🤦🤦🤦
0 · Reply
Ortho91
Ortho91 Jan. 13 at 9:47 PM
$KRYS en fuego
0 · Reply
Stackdoe1
Stackdoe1 Jan. 13 at 9:16 PM
Tomorrow 🫡 ​$PKX $KRYS $KMT $WRBY
0 · Reply
ZacksResearch
ZacksResearch Jan. 12 at 7:13 PM
$KRYS surges 73.9% in a year — what’s driving the momentum? 🚀 🔥 Strong Vyjuvek uptake in 2025 in the US, EU, Japan 🔬 Expanding rare disease pipeline with key programs like KB801 for NK & KB407 for CF 💼 Zacks Rank #1 (Strong Buy) Discover the full growth story here 👉 https://www.zacks.com/stock/news/2816016/krys-reports-preliminary-results-for-2025-outlines-2026-objectives?cid=sm-stocktwits-2-2816016-body-28516&ADID=SYND_STOCKTWITS_TWEET_2_2816016_BODY_28516
0 · Reply
ZacksResearch
ZacksResearch Jan. 12 at 6:13 PM
$KRYS just previewed 2025 — and the numbers are hard to ignore 👀 On a preliminary unaudited basis, Krystal Biotech expects $388$389M in 2025 revenues, ended the year with $955M in cash, and laid out 2026 objectives as the pipeline continues to advance. 💰 Want to see what the 2026 roadmap looks like? Full breakdown here 👉 https://www.zacks.com/stock/news/2816016/krys-reports-preliminary-results-for-2025-outlines-2026-objectives?cid=sm-stocktwits-2-2816016-teaser-28515&ADID=SYND_STOCKTWITS_TWEET_2_2816016_TEASER_28515
0 · Reply
Jessypenny
Jessypenny Jan. 12 at 7:33 AM
$JPM Week is officially here. I'm ​Watching these for major updates: $LLY (Eli Lilly) – Focus is on the obesity market and their oral weight-loss pipeline. Expecting big visionary updates. $KRYS (Krystal Biotech) – Just dropped preliminary FY25 results and presenting today. Watch for data on their rare disease genetic medicine pipeline. $BSX (Boston Scientific) – A top pick for 2026. Looking for growth targets in minimally invasive tech and cardiovascular expansion. $RVMD (Revolution Medicines) – High M&A chatter here. Will we see a formal move from Merck.
0 · Reply
MaxPower1987
MaxPower1987 Jan. 12 at 5:52 AM
0 · Reply
briefingcom
briefingcom Jan. 9 at 1:35 PM
$KRYS: Krystal Biotech (+2.4%) after announcing positive interim clinical update from KB407 phase 1 CORAL-1 study with confirmation of Wild-Type CFTR delivery to the lungs of patients with cystic fibrosis
0 · Reply
Merlintrader
Merlintrader Jan. 9 at 9:56 AM
$KRYS https://www.merlintrader.com/krys-krystal-biotech/
0 · Reply
KatWilliamz
KatWilliamz Jan. 8 at 9:36 PM
$KRYS so far so good 💯💯💯
0 · Reply
BioRich
BioRich Jan. 8 at 9:04 PM
$KRYS One step closer to BO payday. https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-positive-interim-clinical-update-kb407
0 · Reply
BioRich
BioRich Jan. 8 at 9:02 PM
$XBI Let's go!!! $KRYS Positive data! https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-positive-interim-clinical-update-kb407
0 · Reply
BioRich
BioRich Jan. 8 at 2:16 PM
$MLTX For those new, here, you came to the right place. This was over $50 before the previous FDA decision. If I recall, BO rumors (w. merit) were in play at the time. This news this morning should re-rate $MLTX back above $30 so you're still early (always a challenge thinking that after it's run 40%, but I believe that's where it should be sitting...or will after the market fully responds over time). Added to the Hotlist with $CAPR $GUTS $VNDA and $KRYS. Stay tuned folks! Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!
0 · Reply
ZManicItalian
ZManicItalian Jan. 8 at 3:24 AM
$KRYS hopefully we get positive CF insights tomorrow! https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announce-interim-clinical-update-highest-dose
0 · Reply
Vettyspaghetti
Vettyspaghetti Jan. 7 at 11:02 PM
$KRYS I have been in since $125 in 2022. Love this company.
1 · Reply
kenny91655
kenny91655 Jan. 7 at 10:18 PM
$KRYS sold half position AH. Good luck everyone.
0 · Reply